Abstract:Benign prostatic hyperplasia (BPH) is the overgrowth of prostate tissues with high prevalence in older men. BPH pathogenesis is not completely understood, but it is believed to be a result of de novo overgrowth of prostatic stroma. In this study, we show that aberrant activation of transforming growth factor-beta(TGF-beta) mobilizes mesenchymal/stromal stem cells (MSCs) in circulating blood, which are recruited for the prostatic stromal hyperplasia. Elevated levels of active TGF-beta were observed in both a phenylephrine-induced prostatic hyperplasia mouse model and human BPH tissues. Nestin lineage tracing revealed that 39.6% +/- 6.3% of fibroblasts and 73.3% +/- 4.2% smooth muscle cellswere derived from nestin(+) cells in Nestin-Cre, Rosa26-YFPflox/+ mice. Nestin(+) MSCs were increased in the prostatic hyperplasia mice. Our parabiosis experiment demonstrate that nestin+ MSCs were mobilized and recruited to the prostatic stroma of wild-type mice and gave rise to the fibroblasts. Moreover, injection of a TGF-beta neutralizing antibody (1D11) inhibits mobilization of MSCs, their recruitment to the prostatic stroma and hyperplasia. Importantly, knockout of T beta RII in nestin(+) cell lineage ameliorated stromal hyperplasia. Thus, elevated levels of TGF-beta-inducedmobilization and recruitment of MSCs to the reactive stroma resulting in overgrowth of prostate tissues in BPH and, thus, inhibition of TGF-beta activity could be a potential therapy for BPH.

Aberrant Transforming Growth Factor-Beta Activation Recruits Mesenchymal Stem Cells During Prostatic Hyperplasia